State Board of Administration of Florida Retirement System Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

State Board of Administration of Florida Retirement System grew its holdings in Keros Therapeutics, Inc. (NASDAQ:KROSGet Rating) by 28.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,210 shares of the company’s stock after purchasing an additional 1,800 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Keros Therapeutics were worth $227,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Deep Track Capital LP lifted its stake in Keros Therapeutics by 6.2% in the 1st quarter. Deep Track Capital LP now owns 1,380,306 shares of the company’s stock worth $75,061,000 after purchasing an additional 80,306 shares in the last quarter. BlackRock Inc. lifted its stake in Keros Therapeutics by 0.9% in the 1st quarter. BlackRock Inc. now owns 1,298,046 shares of the company’s stock worth $70,588,000 after purchasing an additional 11,520 shares in the last quarter. Vanguard Group Inc. lifted its stake in Keros Therapeutics by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 736,593 shares of the company’s stock worth $40,056,000 after purchasing an additional 2,873 shares in the last quarter. State Street Corp lifted its stake in Keros Therapeutics by 4.4% in the 1st quarter. State Street Corp now owns 683,647 shares of the company’s stock worth $37,177,000 after purchasing an additional 28,655 shares in the last quarter. Finally, First Light Asset Management LLC lifted its stake in Keros Therapeutics by 19.2% in the 1st quarter. First Light Asset Management LLC now owns 658,145 shares of the company’s stock worth $35,790,000 after purchasing an additional 106,047 shares in the last quarter. 79.77% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $46.39 on Tuesday. Keros Therapeutics, Inc. has a fifty-two week low of $24.38 and a fifty-two week high of $68.29. The firm has a 50 day moving average price of $42.85 and a 200 day moving average price of $37.05. The company has a market capitalization of $1.28 billion, a PE ratio of -13.81 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROSGet Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.34. As a group, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on KROS shares. Truist Financial started coverage on shares of Keros Therapeutics in a report on Tuesday, October 18th. They set a “buy” rating and a $100.00 price target for the company. BTIG Research raised their price target on shares of Keros Therapeutics from $80.00 to $95.00 in a report on Tuesday, September 13th.

About Keros Therapeutics

(Get Rating)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.

Read More

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROSGet Rating).

Institutional Ownership by Quarter for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.